The latest price target for BeOne Medicines (NASDAQ:ONC) was reported by Wolfe Research on March 27, 2026. The analyst firm set a price target for $340.00 expecting ONC to rise to within 12 months (a possible 11.44% upside). 30 analyst firms have reported ratings in the last year.

The latest analyst rating for BeOne Medicines (NASDAQ:ONC) was provided by Wolfe Research, and BeOne Medicines initiated their outperform rating.

There is no last upgrade for BeOne Medicines

The last downgrade for BeOne Medicines Ltd happened on March 16, 2026 when Jefferies changed their price target from $420 to $290 for BeOne Medicines Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeOne Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeOne Medicines was filed on March 27, 2026 so you should expect the next rating to be made available sometime around March 27, 2027.

While ratings are subjective and will change, the latest BeOne Medicines (ONC) rating was a initiated with a price target of $0.00 to $340.00. The current price BeOne Medicines (ONC) is trading at is $305.10, which is within the analyst’s predicted range.